url:https://finance.yahoo.com/news/moderna-mrna-reports-q3-earnings-223004747.html
title:Moderna_MRNA_Reports_Q3_Earnings_What_Key_Metrics_Have_to_Say
Moderna (MRNA) reported $1.83 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 45.6%. EPS of -$1.39 for the same period compares to $2.53 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.33 billion, representing a surprise of +37.59%. The company delivered an EPS surprise of +30.85%, with the consensus EPS estimate being -$2.01.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Product sales- United States: $913 million versus the two-analyst average estimate of $314.69 million.
Product sales- Rest of world: $741 million compared to the $703.61 million average estimate based on two analysts.
Product sales- Europe: $103 million versus $235.33 million estimated by two analysts on average.
Revenue- Product sales: $1.76 billion versus $1.28 billion estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -43.7% change.
Revenue- Other revenue: $74 million versus the six-analyst average estimate of $70.42 million.
Revenue- Collaboration revenue: $30 million versus the four-analyst average estimate of $12.89 million. The reported number represents a year-over-year change of -70%.
Revenue- Grant revenue: $44 million versus the three-analyst average estimate of $25.17 million. The reported number represents a year-over-year change of -69.4%.
View all Key Company Metrics for Moderna here>>>Shares of Moderna have returned -30.8% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research